

BioVentrix® Names Dr. Ori Ben-Yehuda as Chief Medical Officer



Brings Extensive Clinical Trial and Patient Care Experience to Senior Management Team

BioVentrix®, Inc., a privately held medical device company focused on the development of less invasive therapies to directly treat the dilated left ventricle and reverse the left ventricular remodeling process of progressive heart failure announced the appointment of Ori Ben-Yehuda, MD as Chief Medical Officer (CMO).

His appointment comes as BioVentrix moves into the advanced stages of its Premarket Approval (PMA) submission for the Revivent TCÖ System.

Dr. Ben-Yehuda is a distinguished clinical cardiologist and clinical trialist with more than 25 years' experience in the treatment of cardiac patients with coronary disease, myocardial infarction, and heart failure. He is currently Professor of Medicine, University of California, San Diego (UCSD). He is also the Editor-in-Chief of *Coronary Artery Disease* and Deputy Editor of *Structural Heart: The Journal of the Heart Team*, both peer-reviewed journals.

Previously, Dr. Ben-Yehuda was the Executive Director of the Clinical Trials Center (CTC) at the Cardiovascular Research Foundation (CRF), one of the world's leading nonprofit organizations specializing in interventional cardiology innovation, research, and education, and Vice President, Cardiovascular Clinical Trials, at Gilead Sciences.

Dr. Ben-Yehuda has personally authored and co-authored over 200 peer-reviewed publications and is the recipient of multiple awards including Top Abstract, TCT Conference 2017, UCSD Department of Medicine Teaching Awards, and Sackler Faculty Prize for Excellence for his MD Thesis.

"We are very pleased to welcome Dr. Ori Ben-Yehuda to BioVentrix as a senior member of our management team," said Jim Dillon, President and CEO, BioVentrix. "His extensive experience with clinical trial management will make a significant difference as we move forward with the ALIVE Expanded Access Program (ALIVE-EAP) and continue to work towards FDA clearance of the Revivent TC System."

"Despite advances in the care of patients with post myocardial infarction heart failure there remains significant unmet need, particularly in patients with significant scar," stated Dr. Ben-Yehuda. "The Revivent TC device allows for a minimally invasive therapy, and I am excited at bringing my clinical trial experience to the BioVentrix team as we implement the ALIVE-EAP trial and bring the ALIVE pivotal trial to its primary endpoint."

Source: [BioVentrix®, Inc](#)

Published on : Wed, 8 Feb 2023